Progressive multifocal leukoencephalopathy in a lung transplant recipient presenting with memory impairment: Case report and literature review. Issue 3 (23rd April 2020)

• Record Type: Journal Article
• Authors: Crowhurst, Thomas; Koszyca, Barbara; Holmes, Mark; Holmes‐Liew, Chien‐Li
• Is Part Of: Transplant infectious disease. Volume 22:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-04-23
• Subjects: demyelination -- immunosuppression -- JC virus -- lung transplantation -- progressive multifocal leukoencephalopathy; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.13293
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Background: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by JC virus (JCV). The disease occurs in the setting of significant immunocompromise and has now been reported in many different settings, although only very rarely after lung transplantation. The mortality rate is high and therapeutic options are limited. Case presentation: We report a case of a 66‐year‐old man who presented with non‐specific memory disturbance at 19 months after lung transplantation for chronic hypersensitivity pneumonitis. He had required methylprednisolone for acute allograft rejection but achieved good graft function. Physical examination was unremarkable. CT revealed hypodensity in the left frontal lobe. MR demonstrated significant hyperintense white‐matter abnormalities on T2‐weighted and fluid‐attenuated inversion recovery (FLAIR) sequences, mainly focused on the periventricular region adjacent the frontal horn of the left lateral ventricle. Brain biopsy confirmed PML. The patient had his immunosuppression reduced but then developed antibody‐mediated rejection four months later. Despite re‐escalation of immunosuppression, he remains neurologically stable on mirtazapine at eight months post‐diagnosis. Conclusions: This very rare case highlights the challenges presented by PML, especially in the lung transplant population. It reveals the difficult balance between reducing immunosuppression to protect the brain versus prevention of lung allograft rejection. It clearly highlights the need for improved therapeutic modalities.